To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Immunohistochemical analy… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas

Journal article
Authors A. M. do Canto
Bmrd Marcelino
J. L. Schussel
B. F. Wastner
L. M. Sassi
L. Correa
R. R. de Freitas
Bengt Hasséus
Göran Kjeller
C. A. Lemos
P. H. Braz-Silva
Published in Clinical Oral Investigations
Volume 23
Issue 2
Pages 779-784
ISSN 1432-6981
Publication year 2019
Published at Institute of Odontology
Pages 779-784
Language en
Keywords Ameloblastoma, Odontogenic tumours, Jaw, Immunohistochemistry, BRAFV600E mutation, Dentistry, Oral Surgery & Medicine
Subject categories Dentistry


ObjectiveThis study aimed to investigate the presence of BRAF V600E mutation in mandible ameloblastomas by correlating clinical and imaging data on the cases studied.MethodsEighty-four cases diagnosed as mandibular ameloblastoma were selected for analysis. The specimens were submitted to immunohistochemistry for detection of BRAF V600E mutated protein. Clinical-pathological data such as age, gender, tumour size, mandibular location, radiographic aspects, histological type and sub-type, and tumour status were collected. The clinical-pathological parameters were categorised and analysed according to BRAF V600E detection.ResultsOf the 84 patients, 78.6% (66 cases) demonstrated positivity for anti-BRAF V600E antibody, whereas 18 were negative (21.4%). The correlation between BRAF expression and variables showed statistical significances for mandibular location (P=0.0353) and tumour size (P=0.008), whereas no statistical significance was observed for gender, age, radiographic aspect, histological pattern, histological sub-type and tumour status. Multivariate logistic regression revealed a significant risk for BRAF positivity in tumours with posterior mandibular location (OR=7.23, P=0.0451) and size >4cm (OR=7.29, P=0.0150).ConclusionBRAF V600E mutation is common in mandibular ameloblastomas, especially in cases of tumours larger than 4cm and in the posterior region of the mandible. In addition, this mutation can occur regardless of histological type of the tumour, age, gender, radiographic aspect and tumour status.Clinical significanceThe association between clinical-pathologic features and BRAF V600E mutation in ameloblastomas may provide directions for the treatment of this neoplasia. The use of BRAF inhibitors for targeted therapy could lead to an establishment of an alternative compared to the resective surgery.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?